Navigation Links
Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments
Date:7/30/2008

- Albuferon(R) Phase 3 trial in genotype 1 hepatitis C completes treatment

phase - - Enrollment of patients into screening completed in second LymphoStat-B(R) Phase 3 trial in systemic lupus erythematosus; completion of randomization

expected in August 2008 - - Initial data from Phase 2 HGS-ETR1 multiple myeloma study expected in

third quarter 2008 -

ROCKVILLE, Md., July 30 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced financial results and key developments for the quarter ended June 30, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )

"During the second quarter, we continued to make excellent progress in our Phase 3 trials of Albuferon(R) in chronic hepatitis C and LymphoStat-B(R) in systemic lupus erythematosus," said H. Thomas Watkins, President and Chief Executive Officer, HGS. "Our timelines to Phase 3 results and the filing of marketing applications are on track for both of these key lead products. Our oncology program also continued to show solid progress. For HGS-ETR1, we expect to have data available from our multiple myeloma trial in the third quarter of 2008, and we will soon complete enrollment in our non-small cell lung cancer trial."

FINANCIAL RESULTS

HGS reported increased revenues for the quarter ended June 30, 2008 of $11.6 million, compared with revenues of $9.0 million for the same period in 2007. Revenues included $8.9 million recognized from the Albuferon agreement with Novartis, and $1.6 million in revenue recognized from the LymphoStat-B agreement with G
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Human Genome Sciences Appoints David P. Southwell to its Board of Directors
2. Human Genome Sciences to Sponsor Conference Call to Discuss Second Quarter 2008 Financial Results
3. New map IDs the core of the human brain
4. BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use
5. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
6. China Biologic Products Announces SFDA Approval for the Production and Sale of Human Albumin 12.5g/vial (25%, 50 ml)
7. MAP Pharmaceuticals Appoints Marco Rosa Vice President of Human Resources
8. Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for Detection of Human Papillomavirus
9. Robots moving closer to humans
10. Highest Replikin Concentrations and Cyclical Behavior Related to Human Mortality Are Found in Malaria Trypanosomes
11. Human Genome Sciences Names Kevin P. McRaith Vice President, Hepatology Franchise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Fla. , Dec. 23, 2014  Rock Creek ... that it has filed a Clinical Trial Application (CTA) ... Healthcare products Regulatory Agency (MHRA) seeking regulatory approval to ... lead molecule, Anatabine Citrate. Contingent on the ... conduct a Phase I trial to assess the safety, ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ - RepliCel Life ... regenerative medicine company focused on the development of autologous ... out of the University of Calgary in conjunction with ... Carolina, which further validates the company,s ongoing clinical research ... effects of pattern baldness. The paper entitled ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 ... peer-reviewed publication of original research, reviews and editorials ... and clinical practice, today published a provocative article ... the development, progression and potential treatment of prostate ... endocrinology research and proposes the possibility that there ...
(Date:12/19/2014)... Charm Sciences is pleased to announce that its ... M1 in raw commingled milk is the first lateral ... peer reviewed report of the validation by Technology and ... Fisheries Research (ILVO-T&V) has been published by the Taylor ... toxic aflatoxin and a known carcinogen, can be passed ...
Breaking Biology Technology:Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2
... week ago, 67 companies were nervously introducing their products ... executives, early adopters, and eager media. , ,DEMOfall 2006 ... flawless. John Patrick's FutureScan panels were smart. The buzz ... was glitch-free. , ,The DEMOgods smiled upon us ...
... including one from California, to stem cell patents held ... lack merit and underscore the need for serious patent ... of challenging patents, such as those held by WARF, ... the United States Patent and Trademark Office ...
... of a directive to provide $5 million in state funding ... state will provide $1 million in state loans and grants ... , ,Thomson, the University of Wisconsin-Madison professor who ... Stem Cell Products, Inc., and Cellular Dynamics International . ...
Cached Biology Technology:Basking (briefly) in the DEMOfall 2006 glow 2WARF challenges show need for patent reform 2WARF challenges show need for patent reform 3WARF challenges show need for patent reform 4State puts up $1 million for James Thomson's new stem cell startup 2State puts up $1 million for James Thomson's new stem cell startup 3
(Date:12/10/2014)... SAN DIEGO , Dec. 9, 2014 ... and collaboration catalyst that provides the connective tissue that ... by enabling them to easily share client-level information; earned ... Foundation to expand to organizations serving seniors aging in ... San Diego" partner on December 11 th 4-6p. ...
(Date:12/5/2014)...  Tute Genomics, a leader in cloud-based solutions for ... funding led by UK-based Eurovestech. Peak Ventures and a ... round. "We are at a pivotal time ... and seeks new approaches for the diagnosis, treatment and ... MBA, and CEO of Tute Genomics. "One of the ...
(Date:11/21/2014)... -- According to a new market research ... Access Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), ... Geography - Global Forecasts to 2020", published by MarketsandMarkets, ... around $25 Billion in 2014 and is expected to ... of 8.69%. Browse 116 market data Tables ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... have shown great success in treating many patients with lung, ... resistance means that many other patients do not respond, and ... A new study from MIT reveals that much of ... cells to circumvent the effects of ErbB inhibitors, allowing them ...
... and the Academy of Science of South Africa are set ... cooperation agreement signed in Pretoria by Leopoldina President Professor Jrg ... Africa, Professor Daya Reddy. The Leopoldina has had ... South Africa for many years, and the 2012/2013 German-South African ...
... Ariz. Improved diagnosis for people afflicted with carpal tunnel ... hand is the goal of a research collaboration led ... a Mayo Clinic physician. Marco Santello and Mark Ross ... for Regenerative Medicine to advance their effort to quantify the ...
Cached Biology News:Why tumors become drug-resistant 2Why tumors become drug-resistant 3Leopoldina signs cooperation agreement with the Academy of Science of South Africa 2ASU-Mayo research project targets carpal tunnel syndrome diagnosis 2
...
Request Info...
LECHNER AND LaVECK MEDIUMfor the clonal growth of normal human bronchial and other epithelial cells. Requires additives. With glutamine.Recommended storage condition:oC to 8oCIntended use(s):research...
The FliTrx Panning Kit is designed to simplify panning for protein-protein interactions with the FliTrx Random Peptide Display Library or the pFliTrx Peptide Display Vector....
Biology Products: